Alert detail
LCD L39614: MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma — WPS
Policy ID: LCD-L39614Specialty: OncologyAdded: 6/5/2026Effective: 2026-05-28lcd
What changed
Covers molecular biomarker testing for skin cancer risk stratification.
Who’s affected: Oncology billing teams · Effective: 2026-05-28
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
Subscribers get the recommended action (“what to do”), the full AI analysis, the LCD revision comparison, and related alerts across your specialty and jurisdiction.
Not ready to subscribe?
Get the free weekly reimbursement brief for Oncology— the week’s changes and deadlines, delivered to your inbox. No account required.